Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
In 2020, the cost of Alzheimer’s in the U.S. is estimated to be over $500 billion, impacting countless patient, family and caregiver lives. If approved, aducanumab may slow clinical decline and potentially help patients maintain independence longer. This could constitute an important breakthrough, after more than 100 clinical programs that have failed in this space. We look forward to engaging meaningfully with ICER and other stakeholders to help ensure that appropriate considerations and data representing the substantial cost and impact to patients, families, and society, as well as the benefits of aducanumab, are applied appropriately and transparently.
The aducanumab Biologics License Application (BLA) is the first for a product that aims to slow the clinical decline of Alzheimer’s disease, as well as one of its hallmarks, the buildup of amyloid plaque. The BLA is currently under priority review with the FDA.
As pioneers in neuroscience, we aim to bring transformative treatments to patients and are deeply committed to making ongoing investments in the science and research required to create breakthrough therapies. We recognize that prices for these treatments – and the ability of patients to obtain access to them – are important concerns for patients, physicians, payers, and policy makers, and we are dedicated to engaging with all stakeholders in a constructive dialogue about innovation, price, and access.
This statement includes forward-looking statements based on Biogen’s current expectations and beliefs that are subject to risks and uncertainties. Biogen’s actual results may differ materially. Please consult the risk factors section of Biogen’s SEC filings.